Agios to Present RISE UP SCD Data at EHA; Reinforces Hemoglobin Signal but Symptom Endpoints Remain Weak

What happened

Agios announced that detailed results from the RISE UP Phase 3 trial of mitapivat in sickle cell disease (SCD) have been selected for the Plenary Abstracts Session at EHA 2026, with a company investor call scheduled for June 13. The news highlights the strength of the hemoglobin response data (40.6% vs 2.9%, p<0.0001) but does not address the non-significant results on sickle cell pain crises (p=0.1213) and fatigue (p=0.7112). This presentation provides increased visibility for the SCD program but does not change the fundamental regulatory risk: the FDA's willingness to accept hemoglobin improvement as a basis for approval remains uncertain. The market's focus will remain on AQVESME launch execution under REMS and the outcome of the Q1 2026 pre-sNDA meeting with the FDA for SCD.

Implication

The EHA presentation is a positive but incremental catalyst. It does not alter the core thesis: AGIO's value hinges on demonstrating that REMS constraints do not cap AQVESME adoption and that the FDA allows an SCD filing based on hemoglobin response. Investors should monitor for concrete operational data from AQVESME (certified prescribers, patient starts) and regulatory updates from the pre-sNDA meeting. The stock's enterprise value remains low (~$0.35B) relative to cash, but the burn rate requires visible commercial traction to avoid dilution risk. We maintain a POTENTIAL BUY rating with a base case of $30, but conviction hinges on near-term checkpoint execution.

Thesis delta

The news reinforces the positive hemoglobin signal from RISE UP but does not address the missed symptom endpoints that are key for FDA acceptance. The thesis shifts slightly toward a higher probability of a constructive FDA engagement given the data's plenary recognition, but the fundamental uncertainty persists. The primary value drivers remain AQVESME launch execution under REMS and the SCD regulatory path; the EHA presentation is a supporting data point, not a game-changer.